louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00780884: Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients
Official title: Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Schizoaffective
Keywords: acupuncture
schizophrenia
insomnia
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2008-10-28
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Insomnia, a common feature of schizophrenia, has serious consequences for daytime functioning and quality of life. Although insomnia is most often treated with medication, a growing number of studies have demonstrated the efficiency of a variety of relaxation techniques, cognitive behavioral therapies and alternative medicine procedures. Acupuncture is among the oldest healing practices in the world. Part of traditional Chinese medicine, acupuncture aims to restore and maintain health through the stimulation of specific points on the body. Previous studies have demonstrated that acupuncture has a positive influence on a number of diseases and disorders, among them Depression, Chronic Pain and Sleep Disorders. Hence, the aim of the present study is to examine the effects of acupuncture as a treatment for insomnia in schizophrenic patients.The study begins with a 7-day, running-in, no-treatment period, followes by an 8-week experimental period. During the experimental period, subjects receive acupuncture treatments twice a week. During the first week of the study (no-treatment period) and the last week of the experimental period, subjects' sleep is monitored with a wrist actigraph, and subjects complete a wide spectrum of questionnaires.


Eligibility criteria: Inclusion Criteria:

1. schizophrenia or schizoaffective disorder - diagnosed according DSM-4.
2. capability to sign inform consent.

Exclusion Criteria:

1. unstable physical illness
2. drug or alchohol abuse or dependence

Primary outcomes:
measure: sleep efficiency
timeFrame: 8 weeks
Secondary outcomes:
measure: anxiety and depression levels
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Haemek Medical Center
Study officials:
affiliation: Haemek Mediacl Center
name: Ilana Kremer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002284: A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
Official title: A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lymphoma, Non-Hodgkin
HIV Infections
Keywords: Lymphoma, Large-Cell
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Zidovudine
Bone Marrow Transplantation
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 12
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.


Eligibility criteria: Exclusion Criteria

Co-existing Condition:

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Concurrent Medication:

Excluded:

* Other anti-retroviral agents.

Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.

Patients must be:

* HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
* At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
* Also patient must fall into one of the following categories:
* Have an HIV seronegative identical twin to serve as a bone marrow donor.
* Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
* Be a good risk candidate for bone marrow transplant.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Hemapheresis Treatment Ctr
state: Maryland
Study officials:
References:
Clinical trial NCT05264584: Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
Official title: Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Disease stage3
Contrast-induced Nephropathy
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2022-03-03
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.

Detailed description: In this randomised non blinded clinical trial, Investigators will study 120 CKD patients undergoing PCI to determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury . So, the patients will be divided into two arms based on block randomization. Each arm compromise 60 patients. The first arm will receive IV hydration and N-acetylcysteine (ctrl arm) . The second arm will receive IV hydration, N-acetylcysteine and Febuxostat (F arm).

Block randomization will be used in this clinical trial design to reduce bias and achieve balance in the allocation of participants to treatment arms.

Eligibility criteria: Inclusion Criteria:

Age ≥ 18 years old .

Patients under treatment of high dose statin(Atorvastatin (40-80 mg/day) .

Glomerular filtration rate=30-59ml/min.

Undergoing coronary PCI.

Exclusion Criteria:

Patients under treatment with febuxostat. Known allergy to febuxostat. High osmolar contrast media during the procedure .

Primary outcomes:
measure: prevention of CI-AKI
timeFrame: 48-72 hours post contrast
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams university hospitals
Study officials:
affiliation: Faculty of medicine Ain shams university
name: Rania Saad, Bachelor
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of medicine Ain Shams university
name: Iman Sarhan, PhD
role: STUDY_DIRECTOR
affiliation: Faculty of medicine Ain Shams university
name: Nahla Teama, PhD
role: STUDY_CHAIR
affiliation: Faculty of medicine Ain Shams university
name: Yasser Alaa, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00873184: Study of Massage Therapy Within a Brain Tumor Setting
Official title: Feasibility Study of Massage Therapy Within a Brain Tumor Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Brain Tumors
Keywords: massage therapy in patients with brain tumors
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Massage Therapy Foundation
First posted: 2009-04-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is

* to assess the feasibility and acceptability of massage therapyto examine the effects of massage therapy
* to explore whether psychological outcomes are associated with changes in patient reported QoL.

Detailed description: As a part of this study, we will provide massage therapy to brain tumor patients. Our contribution here is expected to determine whether massage therapy is safe and helps to improve patient QoL. This contribution is significant because it is expected to provide pilot data on effect sizes so that we may design an adequately powered study to develop massage therapy programs and interventions for patients with brain tumors. In addition to benefiting brain tumor patients, the information from this study may be applied to improving the QoL of other cancer patients.

Eligibility criteria: Inclusion Criteria:

* Patients with histological confirmed, newly diagnosed, post surgical WHO grade III/IV malignant glioma (i.e., glioblastoma, anaplastic astrocytoma) being followed at the Preston Robert Tisch Brain Tumor Center (PRT-BTC) at Duke University Medical Center (DUMC) will be considered potential participants for this study.
* Additional eligibility criteria will be:

  1. \> 18 years old
  2. Karnofsky Performance Score of \> 70 at onset of study
  3. estimated life expectancy of \> 3 months
  4. approval from attending oncologist
  5. the ability to speak, read and write English
  6. live within a 60 mile radius of the DCL
  7. be identified as "stressed" by Perceived Stress Scale (PSS) score, \> 12.1 and 13.7 for men and women respectively, and 8) signed informed consent prior to initiation of study-related procedures.

Exclusion Criteria:

* N/A

Primary outcomes:
measure: To assess the feasibility and acceptability of massage therapy provided to primary brain tumor patients. This assessment will integrate data about patient eligibility rates, patient participation rates, patient adherence rates, and adverse events.
timeFrame: 6 months
Secondary outcomes:
measure: To examine the effects of massage therapy on psychological outcomes related to stress, distress, anxiety, and depression in this population and to explore whether psychological outcomes are associated with changes in patient reported QoL.
timeFrame: 12 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Stephen Keir, Dr.Ph,MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00477984: Effects of Alcohol on Simulated Driving
Official title: The Effects of Five Dosages of Ethanol on Simulated Driving Performance and Event-Related Potentials
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcoholism
Keywords: Alcohol
Driving
Multitasking
ERP
social drinkers
Lead sponsor: Utrecht Institute for Pharmaceutical Sciences
Sponsor class: OTHER
First posted: 2007-05-24
Enrollment: 32
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Previous studies have shown that alcohol significantly impairs driving performance. Acute alcohol administration also has a detrimental effect on secondary task performance during dual-tasks. The present study will investigate the effects of five different dosages of ethanol (0,0.2, 0,5, 0,8 and 1,0 % BAC) on performance in a driving simulator. Steering performance and brain activity will be recorded in both single- and dual-task conditions.


Eligibility criteria: Inclusion Criteria:

* He/she is aged between 21-50
* Written informed consent
* Right-handed
* Normal static binocular acuity, corrected or uncorrected
* Normal hearing
* Social Drinker (average of 7 to 21 alcoholic drinks per week)
* Possession of a drivers license
* Be considered as reliable and mentally capable of adhering to the protocol.

Exclusion Criteria:

* Current drug use (positive urine drug screen on the presence of amphetamines (including MDMA), barbiturates, cannabinoids, benzodiazepines, cocaine, and opiates)
* Positive urine pregnancy drug screen in women
* Use of psychoactive medication
* Positive alcohol breath test
* Prior enrolment in the same study
* Physical or mental illness
* Excessive alcohol use (\>21 alcoholic drinks per week)
* Excessive smoking (more than 10 cigarettes per day)
* Intake of caffeine-containing beverages over 5 glasses per day

Primary outcomes:
measure: Primary parameter of the steering simulator is the standard deviation of the car from the center of the road (steering error).
timeFrame: 5 testdays
Secondary outcomes:
measure: Reaction speed after hearing the deviant target tone. Brain activity: ERPs of interest are the mismatch negativity (MMN), P3a, P3b, and reorienting negativity (RON)
timeFrame: 5 testdays
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: Utrecht Institute for Pharmaceutical Sciences
Study officials:
affiliation: Utrecht Institute for Pharmaceutical Sciences
name: Joris C Verster, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Utrecht Institute for Pharmaceutical Sciences
name: Edmund R Volkerts, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04210284: Oral Nutritional Optimization in Total Joint Arthroplasty
Official title: Oral Nutritional Optimization in Total Joint Arthroplasty
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Osteoarthritis
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2019-12-24
Enrollment: 372
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect on hematological markers of nutritional intervention on nutritionally deficient patients following total joint replacement surgery.

Detailed description: Numerous pre-operative modifiable variables have been extensively investigated for their effect on outcomes in TJA. These include metabolic diseases such as diabetes mellitus, obesity, and smoking status. However, nutritional status has not been as thoroughly investigated; to date, no prospective randomized control study has assessed the effect of oral nutritional supplementation for malnourished patients. This study will be a novel investigation into the role for routine serum screening for malnutrition as well as oral nutritional supplementation in TJA patients. This study could serve as a stepping stone towards creating a new pathway to highlight at-risk patients and pre-operatively optimizing their outcomes after TJA.

Eligibility criteria: Inclusion Criteria:

1. Patient are current candidates for elective primary total hip and total knee arthroplasty
2. Patients ≥55 years of age but ≤ 95
3. Patients who meet at least one of the following three laboratory criteria for malnutrition:

TSerum Albumin: ≤3.5 mg/dl Pre-Albumin: \<15 mg/dl Transferrin: \<200 mg/dl

Exclusion Criteria:

1. Previous history of septic arthritis
2. Allergy to oral supplementation
3. Inability to consume oral supplementation
4. Protein malabsorption syndromes
5. Eating disorders
6. End stage renal and hepatic disease
7. Revision surgery, non-elective surgery, hemiarthroplasty, and unicompartmental knee arthroplasty

Primary outcomes:
measure: Changes in the patients' albumin, pre-albumin, and/or transferrin levels
timeFrame: Visit 2 (2 wks pre) Visit 3 (surgery day) Visit 5 (4 weeks post)
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Philadelphia
country: United States
facility: Rothman Orthopedic Institute
state: Pennsylvania
Study officials:
affiliation: NYU Langone
name: Ran Schwarzkopf
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00457184: Thrombophilia and Migraine, Are They Related?
Official title: Thrombophilia and Migraine, Are They Related? - A Clinical Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Migraine
Thrombosis
Thrombophilia
Keywords: Migraine
Thrombosis
Thrombophilia
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2007-04-05
Enrollment: 50
Sex: ALL
Minimum age (years): 5
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Migraine was described as related to stroke in adults and children as well. Complete thrombophilic status was not study in large groups of pediatric patients. The purpose of our study is to assess the prethrombotic profile among children and teenagers diagnosed as suffering from migraine attacks.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed as suffering from migraine according to the Neurologic criteria.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Afula
country: Israel
facility: Pediatric Hematology Unit - HaEmek Medical Center
Study officials:
affiliation: Pediatric Hematology Unit, Ha'Emek Medical Center
name: Ariel Koren, MD
role: STUDY_DIRECTOR
affiliation: Pediatric Neurology Unit - Ha'Emek Medical Center
name: Miriam Kutai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05677984: Awaken Prone Positioning Ventinlation in COVID-19 Patients
Official title: Comparison the Prescription of Duration of Awaken Prone Positioning Ventilation Duration in COVID-19 Patients: a Randomised Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2023-01-10
Enrollment: 409
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Awaken prone positioning (APP) ventilation has been widely accepted as a standard regimen in the management of COVID-19 patients. Physiological studies have proved ventilation/perfusion improvement during APP in COVID-19, which was associated improved oxygenation. However, the optimal duration for APP was not yet demonstrated. In this study, we aimed at the prolonged APP to see whether this could improve patients outcomes.


Eligibility criteria: Inclusion Criteria:

* Aged \> 18-yr to 85-yr
* Severe COVID-19 pneumonia (with typical radiographic alternations) and non-intubated patients.
* SpO2 \<= 93% with ambient air at rest.
* PaO2/FiO2 \<= 300 mmHg

Exclusion Criteria:

* Definite intolerance to APP (e.g. pregnancy, extremity deformity, recent fracture, open thoracic or abdominal surgery, pace-maker implant in recent 48-hr, spine stability, pelvis or facial fractures, predicted difficult airway)
* morbidity obesity, BMI \> 40
* consciousness disorder (GCS \< 13), delirium dementia
* hemodynamic instability (with norepinephrine \>20 ug/min )
* NYHA Grade III or IV
* Severe hemoptysis
* long term home oxygenation of CPAP
* Refuse invasive mechanical ventilation (DNI DNR)

Primary outcomes:
measure: 28-day intubation rate
timeFrame: follow-up till 28-day
Secondary outcomes:
measure: APP duration/days
timeFrame: follow-up till APP ended, daily duration of APP also recoreded, up to 7 days
measure: Application of HFNC NIV vasopressor CRRT ECMO sedation, or complication
timeFrame: follow-up till 28-day
measure: mortality (ICU hospital) length of ICU (hospital) stay
timeFrame: follow-up during the ICU/hospital stay, up to 28 days
Other outcomes:
measure: Adverse events of interest
timeFrame: 28 post-randomisation
Locations:
city: Nanjing
country: China
facility: Southeast University
state: Jiangsu
Study officials:
affiliation: Southeast University
name: Haibo QIU, Dr
role: STUDY_DIRECTOR
References:
Clinical trial NCT02066584: The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization (IVF) Outcome of Sibling Oocytes
Official title: The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization Outcome of Sibling Oocytes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: sibling oocytes
glucose
culture media
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2014-02-19
Enrollment: 600
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Sibling oocytes retrieved from women who have undergone IVF treatment in our IVF unit.

Brief summary: The importance of glucose in culture media on fertilization and embryo development is still controversial. Although it has been reported that glucose is essential for fertilization process and biosynthesis of membrane lipid and nucleic acids, comparatively high levels of glucose in culture media may cause developmental arrest of cleavage stage embryos. The aim of this retrospective study is to examine whether exposure of sibling oocytes to different concentrations of glucose in culture media has any further effect on IVF outcome.

Detailed description: This retrospective study will include data from either standard IVF or Intracytoplasmic Sperm Injection (ICSI) cycles, in which sibling oocytes were equally divided and incubated separately in one of the following pairs of culture media:

1. Universal IVF medium vs. ISM1 medium ( Origio, Medi-Cult)
2. P1 medium vs. ECM medium (Irvine).

Fertilization rate,as well as embryo cleavage rate and morphology will be evaluated.

Eligibility criteria: Inclusion Criteria:

* Sibling oocytes from cycles where at least 4 oocytes were retrieved

Exclusion Criteria:

* Less than 4 oocytes retrieved
* Partner has undergone testicular sperm extraction (TESE)

Primary outcomes:
measure: Fertilization Rate
timeFrame: 2 years
Secondary outcomes:
measure: Embryo Quality
timeFrame: 2 years
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
affiliation: Hellel Yaffe Medical Center
name: Medeia Michaelo, PhD
role: PRINCIPAL_INVESTIGATOR
References: